Livanova Plc

Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
www.livanova.com

Earnings Score
Moat Score
Safety Score

Market Cap $2.69B
PE 114
Debt $647.49M
Cash $666.58M
EV $2.67B
FCF $108.67M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$23.68M
EBIT	$13.36M
ROE	2%
ROA	1%
FCF	$108.67M
Equity	$1.31B
Growth Stability	1
PE	113.76
PB	2.06
P/FCF	24.79
P/S	2.17
Price/Cash	0.25
Debt/Equity	0.49
Debt/FCF	5.96
Net Margins	1%
Gross Margins	68%
Op. Margins	1%
Earnings CAGR	-1%
Sales Growth YoY	11%
Sales Growth QoQ	-0%
Sales CAGR	6%
FCF CAGR	-2%
Equity CAGR	16%
Earnings Stability	0.01
Earnings Growth YoY	-550%
Earnings Growth QoQ	102%

Sales CAGR 5Y	4%
FCF CAGR 5Y	2%
Equity CAGR 5Y	-1%
Earnings CAGR 3Y	8%
Sales CAGR 3Y	8%
FCF CAGR 3Y	-9%
Equity CAGR 3Y	0%
Market Cap	$2.69B
Revenue	$1.24B
Assets	$2.52B
Total Debt	$647.49M
Cash	$666.58M
Shares Outstanding	54.19M
EV	2.67B
Earnings Score	6%
Moat Score	27%
Safety Score	83%
Final Score	39%
Working Capital	768.71M
Current Ratio	3.37
Gross Profit	$841.69M
Shares Growth 3y	1%
Equity Growth QoQ	5%
Equity Growth YoY	7%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients healthcare professionals and healthcare systems. At LivaNova we understand the importance of bringing both clinical and economic value to our customers. We are a strong market-leading medical technology and services company offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol LIVN. LivaNova has approximately 3000 employees worldwide. We are headquartered in London UK and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in advanced circulatory support cardiopulmonary and neuromodulation dedicated to creating meaningful products and therapies that transform lives each and every day.

SEC Filings

Direct access to Livanova Plc (LIVN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Livanova Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Livanova Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -1%

Stability 1%

loading chart...

Livanova Plc Discounted Cash Flow

Fully customizable DCF calculator online for Livanova Plc.

Years

Calculation mode

= $950M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$109M	$106M	$104M	$102M	$100M	$98M	$96M	$94M	$92M	$91M	$89M	$888M
DCF		$97M	$86M	$77M	$68M	$61M	$54M	$48M	$43M	$38M	$34M	$342M
Value	$950M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-5%	-2%	-17%	-14%	-37%	-13%	-8%	2%	1%
ROA	2%	5%	-9%	-7%	-11%	-0%	-1%	-1%	1%
ROE	-4%	-1%	-13%	-11%	-31%	-10%	-7%	1%	2%

Bad Net Margins (0.79%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	3.18	3	2.32	-3.56	-6.69	6.86	14.27	16.1	5.96
Debt over Equity	0.1	0.09	0.13	0.3	0.68	0.41	0.51	0.5	0.49
Growth Stability	-	-	-	-	-	-	-	-	1

Bad Debt/FCF ratio (5.96)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.49)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-17%	9%	-2%	-14%	11%	-1%	13%	4%
Earnings YoY growth	-	-60%	655%	-18%	122%	-61%	-36%	-120%	-
Equity YoY growth	-	6%	-17%	-8%	-19%	16%	-7%	6%	-1%
FCF YoY growth	-	7%	44%	-240%	-1%	-167%	-44%	-8%	2%